Catalyst Capital Advisors’s Gilead Sciences GILD Stock Holding History

Catalyst Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-75	Closed	-$26K	–	469
2016 Q1	$26K	Hold	75	–	–	﹤0.01%	390
2015 Q4	$67K	Hold	75	–	–	0.01%	344
2015 Q3	$81K	Hold	75	–	–	0.01%	341
2015 Q2	$166K	Buy	+75	New	+$8.2K	0.02%	322

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Catalyst Capital Advisors's GILD Position: Q2 2026 in Review

Catalyst Capital Advisors reduced its Gilead Sciences (GILD) stake by 24% in Q2 2026, selling an estimated $13.3K and leaving 320 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #306.

Catalyst Capital Advisors first reported a position in GILD in Q2 2013 and has held it in 42 quarters since. The position peaked at $15.1M in Q4 2015. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Catalyst Capital Advisors held 320 shares of Gilead Sciences worth $40.4K as of Q2 2026.
Catalyst Capital Advisors sold 101 Gilead Sciences shares in Q2 2026, an estimated $13.3K.
Gilead Sciences made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #306 holding.
Catalyst Capital Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 42 quarters since.
Catalyst Capital Advisors's Gilead Sciences position peaked at $15.1M in Q4 2015.
690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.